These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25488804)

  • 1. Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
    Kovacs RJ; Maldonado G; Azaro A; Fernández MS; Romero FL; Sepulveda-Sánchez JM; Corretti M; Carducci M; Dolan M; Gueorguieva I; Cleverly AL; Pillay NS; Baselga J; Lahn MM
    Cardiovasc Toxicol; 2015 Oct; 15(4):309-23. PubMed ID: 25488804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
    Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
    Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
    Rodon J; Carducci MA; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly AL; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
    Clin Cancer Res; 2015 Feb; 21(3):553-60. PubMed ID: 25424852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
    Fujiwara Y; Nokihara H; Yamada Y; Yamamoto N; Sunami K; Utsumi H; Asou H; TakahashI O; Ogasawara K; Gueorguieva I; Tamura T
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1143-52. PubMed ID: 26526984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
    Rodón J; Carducci M; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly A; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
    Invest New Drugs; 2015 Apr; 33(2):357-70. PubMed ID: 25529192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
    Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
    PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
    Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
    Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
    J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
    Wick A; Desjardins A; Suarez C; Forsyth P; Gueorguieva I; Burkholder T; Cleverly AL; Estrem ST; Wang S; Lahn MM; Guba SC; Capper D; Rodon J
    Invest New Drugs; 2020 Oct; 38(5):1570-1579. PubMed ID: 32140889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
    Liu X; Yu M; Chen Y; Zhang J
    Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell.
    Zhang Q; Guo W; Di C; Lou M; Li H; Zhao Y
    Pol J Pathol; 2017; 68(4):312-317. PubMed ID: 29517201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain perfusion and permeability in patients with advanced, refractory glioblastoma treated with lomustine and the transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate.
    Sepulveda-Sanchez J; Ramos A; Hilario A; DE Velasco G; Castellano D; Garcia DE LA Torre M; Rodon J; Lahn MF
    Oncol Lett; 2015 Jun; 9(6):2442-2448. PubMed ID: 26137087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model.
    Gueorguieva I; Cleverly AL; Stauber A; Sada Pillay N; Rodon JA; Miles CP; Yingling JM; Lahn MM
    Br J Clin Pharmacol; 2014 May; 77(5):796-807. PubMed ID: 24868575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.
    Zhou L; McMahon C; Bhagat T; Alencar C; Yu Y; Fazzari M; Sohal D; Heuck C; Gundabolu K; Ng C; Mo Y; Shen W; Wickrema A; Kong G; Friedman E; Sokol L; Mantzaris I; Pellagatti A; Boultwood J; Platanias LC; Steidl U; Yan L; Yingling JM; Lahn MM; List A; Bitzer M; Verma A
    Cancer Res; 2011 Feb; 71(3):955-63. PubMed ID: 21189329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
    Gore J; Imasuen-Williams IE; Conteh AM; Craven KE; Cheng M; Korc M
    Cancer Lett; 2016 Aug; 379(1):143-53. PubMed ID: 27267807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
    Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells.
    Gao Y; Shan N; Zhao C; Wang Y; Xu F; Li J; Yu X; Gao L; Yi Z
    Int J Clin Exp Pathol; 2015; 8(5):4923-32. PubMed ID: 26191185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A polyethylenimine-modified carboxyl-poly(styrene/acrylamide) copolymer nanosphere for co-delivering of CpG and TGF-β receptor I inhibitor with remarkable additive tumor regression effect against liver cancer in mice.
    Liang S; Hu J; Xie Y; Zhou Q; Zhu Y; Yang X
    Int J Nanomedicine; 2016; 11():6753-6762. PubMed ID: 28008250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
    Maier A; Peille AL; Vuaroqueaux V; Lahn M
    Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.